Group 1 - Multiple listed companies are developing detection solutions for Chikungunya virus, including Kingmed Diagnostics, Wanfu Biology, and Shengxiang Biology [1][2] - Kingmed Diagnostics has established a comprehensive platform for serological, fluorescent PCR, and sequencing tests to accurately identify the Chikungunya virus, aiding in clinical diagnosis [1] - Wanfu Biology has responded to the recent guidelines from the National Disease Control Bureau by developing several detection products that create a closed-loop system for rapid screening, precise detection, and monitoring [1] - Shengxiang Biology has introduced a dual-platform solution combining rapid nucleic acid testing and sequencing for precise tracing, with a detection time of 25 to 45 minutes and high sensitivity [1] Group 2 - According to a report by Everbright Securities, several domestic listed companies, including Da'an Gene, Wanfu Biology, Shengxiang Biology, Zhijiang Biology, Shuoshi Biology, Mingde Biology, and Rendu Biology, have launched Chikungunya virus detection solutions [2]

Group 1 - The core point of the article is that Wanfu Biology announced the approval of its investment in Saiweisen Technology's "Cervical Cell Digital Pathology Image Assisted Diagnosis Software," marking a significant milestone in the field of cervical cytology with the first AI-assisted diagnosis Class III product registration in the country [1] - The AI-assisted reading of slides significantly enhances diagnostic efficiency and accuracy, providing more precise treatment plans for patients [1] - Saiweisen is committed to offering a comprehensive solution for intelligent pathology AI-assisted diagnosis and aims to continue innovating in the pathology AI field, promoting the digital transformation of the industry [1]

证券日报网讯万孚生物（300482）7月31日在互动平台回答投资者提问时表示，2025年6月18日，公司召 开第五届董事会第十二次会议，审议通过了《关于终止实施2024年限制性股票激励计划暨回购注销限制 性股票的议案》并已经2025年第一次临时股东大会审议通过，公司结合实际情况，决定终止实施2024年 限制性股票激励计划。 ...

Core Viewpoint - The company has made significant advancements in the AI sector, particularly in the field of cervical cytology, with the approval of an AI-assisted diagnostic software, marking a milestone in digital pathology [2] Company Summary - Wanfu Biology (300482.SZ) announced on July 30 that its investment in Saiweisen Technology's "Cervical Cell Digital Pathology Image Assisted Diagnosis Software" has received formal approval, becoming the first AI-assisted diagnostic Class III product registration in the national cervical cytology field [2] - This approval signifies a new milestone for the "Digital Pathology + AI Assistance" model, which enhances diagnostic efficiency and accuracy through AI-assisted slide reading, providing more precise treatment plans for patients [2] - Saiweisen is committed to offering a comprehensive solution for intelligent pathology AI-assisted diagnosis, and with the company's support, it will continue to deepen its focus on the pathology AI field, driving the development and application of more innovative technologies [2] Industry Summary - The approval of the AI-assisted diagnostic software is expected to contribute to the digital transformation of the pathology industry, providing higher quality and smarter pathology solutions for doctors and patients [2]

Core Viewpoint - The company Wanfu Biology (300482) has received a medical device registration certificate from the National Medical Products Administration for its human microsatellite instability (MSI) detection kit, which is significant for various solid tumor patients [1] Group 1: Product Significance - The MSI detection is important for screening Lynch syndrome [1] - It aids in the selection of 5-FU chemotherapy drugs [1] - The test is also used for prognostic stratification and identifying beneficiaries of immune checkpoint inhibitors [1]

证券日报网讯 万孚生物7月30日在互动平台回答投资者提问时表示，海外竞争方面，目前公司产品已经 覆盖全球超过150个国家和地区，对海外当地商业模式及政策合规有着深入的了解，且公司技术平台布 局齐全，项目丰富，可以满足当地市场需求。 （编辑 袁冠琳） ...

Core Viewpoint - The company is actively focusing on the pet health market by leveraging its expertise in the field of in vitro diagnostics to develop diagnostic products for pets [1] Group 1: Company Initiatives - The company has a range of existing diagnostic platforms, including immunofluorescence testing, coagulation testing, blood gas and electrolyte testing, biochemical testing, molecular diagnostics, sperm quality testing, white blood cell testing, and an intelligent testing app called "Pet Health" [1] - "Pet Health" is a pioneering initiative by the company that integrates traditional laboratory functions into a cloud-based platform, enabling mobile laboratory services to provide rapid, accurate, and comprehensive testing and diagnostic support for the animal healthcare industry [1]

证券日报网讯万孚生物（300482）7月30日在互动平台回答投资者提问时表示，公司暂无针对血铅检测 的相关产品。 ...

证券日报网讯万孚生物（300482）7月30日在互动平台回答投资者提问时表示，公司时刻关注呼吸道传 染病市场需求动态变化，努力为患者提供更高效、更全面的快检筛查服务，满足市场的检测需求。具体 产品销售情况请留意公司相关公告。 ...

证券日报网讯万孚生物（300482）7月30日在互动平台回答投资者提问时表示，多年前公司在美国圣地 亚哥布局了本地化工厂，已具备量产的能力，可随时满足当地客户的本地化生产需求。 ...